By Michael Gwarisa For decades, scientists have battled the elusive human immunodeficiency virus (HIV), whose ability to mutate and develop resistance has defeated one vaccine candidate after another. Now, a groundbreaking clinical trial under way in Zimbabwe and South Africa aims to outsmart the virus by targeting its most vulnerable, unchanging parts. The investigational vaccine,